Ascendis Pharma A (ASND) Short term Debt (2026)

Ascendis Pharma A has reported Short term Debt for 6 years, with the latest figure at $864.8 million in Q1 2026.

• Quarterly Short term Debt rose 31.72% year-over-year to $864.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $864.8 million (up 31.72% YoY) and the FY2025 annual result came in at $798.1 million, up 63.0% from the prior year.
• Short term Debt advanced to $864.8 million in Q1 2026 per ASND's latest filing, from $798.1 million in the prior quarter.
• Over five years, Short term Debt peaked at $864.8 million in Q1 2026 and troughed at $10.0 million in Q1 2022.
• A 5-year average of $399.4 million and a median of $489.6 million in 2024 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2023 and 2024: Short term Debt slumped 36.48% in 2023, then soared 4937.49% in 2024.
• Over 5 years, Short term Debt stood at $11.9 million in 2022, then jumped by 3591.46% to $438.0 million in 2023, then increased by 11.79% to $489.6 million in 2024, then surged by 63.0% to $798.1 million in 2025, then climbed by 8.36% to $864.8 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $864.8 million, $798.1 million, and $771.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.